The paradigm shift in CV Risk prevention: Statins
The paradigm shift in CV Risk prevention: StatinsJohn Kastelein, MDAcademic Medical Centre Amsterdam, The Netherlands Slides presented by the faculty during this PACE Master Class For educational purposes only. Click on the slides to review |
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
Share this page with your colleagues and friends: